https://orcid.org/0000-0002-5060-0819
References
- Desouky E. Urological surgery in the COVID-19 era: patient counselling and informed consent. Arab J Urol. 2020;18:62–64.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776.
- Desouky E. COVID-19 impact on urology practice: a possible dilemma of misdiagnosis. Arab J Urol. 2020;18:59–61.
- Balar AV, Kulkarni GS, Uchio EM, et al. Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). J Clin Oncol. 2019;37(Suppl.):350.
- Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–427.
- Kuusk T, Szabados B, Liu WK, et al. Cytoreductive nephrectomy in the current treatment algorithm. Ther Adv Med Oncol. 2019;11:1758835919879026.
- Silbermann M, Pitsillides B, Al-Alfi N, et al. Multidisciplinary care team for cancer patients and its implementation in several Middle Eastern countries. Ann Oncol. 2013;24(Suppl. 7):vii41–vii47.